A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
BGB-53038-101
Phase 1 other active
Quick answer
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification for Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications is a Phase 1 program (other) at Beone Medicines Ireland Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beone Medicines Ireland Limited
- Indication
- Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications
- Phase
- Phase 1
- Modality
- other
- Status
- active